Citryll, an Oss, Netherlands-based pharmaceutical company, held the first closing of a targeted €15m round.
Backers included ModiQuest B.V., BOM Brabant Ventures, BrightGene, and Curie Capital.
Founded by ModiQuest B.V., originator of the tACPA patents, Helmuth van Es, CEO, and Renato Chirivi, CSO and co-inventor of tACPA, Citryll is a private pharmaceutical company dedicated to the development and commercialization of therapeutics that target NETosis and NETs.
The proceeds will be used to progress the pre-clinical and clinical development of its tACPA antibodies, inhibitors of neutrophil extracellular traps (NETs) and their formation (NETosis). tACPA interferes with the formation, function and clearance of NETs, but downstream of the peptidylarginine deiminase (PAD) dependant citrullination pathway. It does so by binding to N-terminal citrullinated epitopes in histones that are essential for NET formation.